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746Summary
Tyrosine kinase 2 (Tyk2) is a nonreceptor tyrosine ki-
nase that belongs to the Janus kinase (Jak) family.
Here we identified a homozygous Tyk2 mutation in
a patient who had been clinically diagnosed with
hyper-IgE syndrome. This patient showed unusual
susceptibility to various microorganisms including vi-
rus, fungi, and mycobacteria and suffered from atopic
dermatitis with elevated serum IgE. The patient’s cells
displayed defects in multiple cytokine signaling path-
ways including those for type I interferon (IFN), inter-
leukin (IL)-6, IL-10, IL-12, and IL-23. The cytokine sig-
nals were successfully restored by transducing the
intact Tyk2 gene. Thus, the Tyk2 deficiency is likely
to account for the patient’s complex clinical manifes-
tations, including the phenotype of impaired T helper
1 (Th1) differentiation and accelerated Th2 differentia-
tion. This study identifies human Tyk2 deficiency and
demonstrates that Tyk2 plays obligatory roles in mul-
tiple cytokine signals involved in innate and acquired
immunity of humans, which differs substantially
from Tyk2 function in mice.
Introduction
The majority of helical bundled cytokines transduce
their signals via the Janus kinase (Jak) family kinases
that are constitutively associated with cytokine recep-
tors. Four mammalian Jak proteins have been described
to date: Jak1, Jak2, Jak3, and Tyk2 (Ihle, 1995; Liu et al.,
1998; O’Shea et al., 2002). When cytokines bind to their
corresponding receptors expressed on the cell surface,
receptor-associated Jaks are activated, and they in turn
phosphorylate both cytokine receptors and neighboring
Jaks. Phosphorylation of specific tyrosine motifs in the
cytokine receptors provides docking sites for signal
transducers and activators of transcription (STAT), and
STATs recruited to the receptor are phosphorylated by
the Jaks. Upon phosphorylation, STATs dimerize via
their Src homology domain-2 (SH2) domains and trans-
locate to the nucleus, where they activate different
genes. Recent studies have demonstrated that several
inhibitory mechanisms are involved in the regulation of
the Jak-STAT pathway to prevent it from overactivation,
including SOCS (suppressor of cytokine signaling) pro-
teins that are induced through the Jak-STAT pathway
to make a negative feedback loop (Alexander and Hilton,
2004).
The functional importance of the Jaks was first inves-
tigated in studies that used cell lines defective in cyto-
kine signaling and was subsequently confirmed by the
establishment of Jak-deficient mice (Velazquezet al.,
1992; Muller et al., 1993; Neubauer et al., 1998; Nosaka
et al., 1995; Parganas et al., 1998; Park et al., 1995; Rodig
et al., 1998). Jak12/2 mice die perinatally and exhibit
profound defects in lymphoid development (Rodig
et al., 1998). Analyses of cells from Jak12/2mice demon-
strated that Jak1 is essential for signaling by type I and II
IFN, in agreement with prior studies that used human
mutant cell lines. Jak22/2mice show embryonic lethality
due to failure of erythropoiesis, while Jak32/2 mice suf-
fer from severe combined immunodeficiency in accordwith observations for human Jak3 deficiency (Macchi
et al., 1995; Russell et al., 1995). These findings clearly
demonstrated the nonredundant roles of Jak1, Jak2,
and Jak3 in signaling through the corresponding cyto-
kine receptors.
Tyk2 is the first member of the Jak kinase family to be
isolated and was originally described as essential for
type I IFN signaling in a human fibroblast cell line (Firm-
bach-Kraft et al., 1990; Velazquez et al., 1992). However,
the establishment of Tyk2-deficient mice revealed that
Tyk2 was not absolutely essential for type I IFN signaling
in mice (Karaghiosoff et al., 2000; Shimoda et al., 2000).
Tyk22/2 mice displayed a lack of responsiveness to
a small amount of IFNa, but a high concentration of
IFNa could fully transduce its signals even in the ab-
sence of Tyk2. Although Tyk2 is a component of several
other cytokine signaling pathways, including those of IL-
6 and IL-12 (Bacon et al., 1995; Ihle, 1995; Stahl et al.,
1994), in Tyk22/2 mice the IL-6-mediated signals are es-
sentially normal and IL-12 signaling is partially impaired.
Thus, the function of Tyk2 in mice appears to be com-
pensated for in vivo, partly by other kinase(s), most likely
other Jak(s). Whether the discrepancy in the stringency
of Tyk2 requirement in cytokine signaling between the
human cell lines and the mutant mice can be attributed
to the difference between established cell lines and pri-
mary cells or the species difference as observed in sev-
eral primary immunodeficiencies such as the Btk, BLNK,
or l5 deficiency has been unclear (Conley et al., 2000;
Minegishi et al., 1998, 1999b).
In the present study, we investigated immunological
abnormalities in a patient who had been clinically diag-
nosed with hyper-IgE syndrome (HIES). HIES is a unique
primary immunodeficiency, characterized by recurrent
skin abscesses, pneumonia, and highly elevated serum
IgE (Grimbacher et al., 2005). Its etiology is totally un-
known even though the autosomal dominant or reces-
sive inheritance has been reported (Grimbacher et al.,
1999a; Renner et al., 2004). The patient investigated in
this study showed susceptibility to various microorgan-
isms including virus, fungi, and mycobacteria and suf-
fered from atopic dermatitis with elevated serum IgE.
Peripheral blood cells from the patient showed almost
complete defects in both IL-12 and IFNa/b signaling,
prompting us to identify a homozygous mutation of
Tyk2 in this patient, a signaling component shared by
both cytokines. The patient’s cells also displayed severe
defects in IL-6 and IL-10 signaling, in contrast to previ-
ous observations in Tyk2-deficient mice. Transduction
of the intact Tyk2 gene rescued the patient’s cells from
the cytokine signaling defects. Thus, the present study
identified human Tyk2 deficiency as a type of primary
immunodeficiency displaying the phenotype of the au-
tosomal recessive HIES accompanied by susceptibility
to intracellular bacterial infection and highlighted
a unique and indispensable role played by Tyk2 in the
innate and acquired immune responses in humans.
Results
Both IL-12 and IFNa Signaling Pathways Are
Defective in T Cells from a Patient with HIES
We investigated, from an immunological point of view,
a 22-year-old Japanese male who had been clinically
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747diagnosed as HIES. According to the HIES scoring sys-
tem developed by the NIH group (Grimbacher et al.,
1999b), the patient scored 48 points, similar to those
with typical HIES (see Experimental Procedures). He
showed complex clinical manifestations, including sus-
ceptibility to various types of microorganisms (virus, in-
tracellular and extracellular bacteria, and fungi), atopic
dermatitis-like skin inflammation starting from 1 month
of age, and a high amount of serum IgE (2100 IU/ml).
He has suffered recurrently from otitis media, sinusitis,
pneumonias, skin abscesses, oral candidiasis, mollus-
cum contagiosum, and herpes simplex infection in skin
and mucosa. He also experienced an episode of Bacille
Calmette-Guerin (BCG) infection at 22 months and non-
typhi salmonella gastroenteritis at 15 years of age. The
numbers of T, B, and NK cells in the peripheral blood
were all within the normal range, and neutrophils
showed normal functions in laboratory tests (data not
shown). The patient’s parents are consanguineous, indi-
cating a possible recessive hereditary disorder. Be-
cause the patient experienced an infection with BCG,
we first analyzed the genes encoding IL-12 p40, IL-
12Rb1, IFNGR1, IFNGR2, and STAT1, which have been
identified as responsible genes for primary immunodefi-
ciency with susceptibility to mycobacterial infection
(Casanova and Abel, 2004). No mutation was detected
in any of the corresponding cDNAs isolated from the
patient (data not shown).
We next examined whether the patient had any defect
in IL-12 signaling. When peripheral blood mononuclear
cells (PBMCs) from the patient were stimulated with mi-
togens, IL-12 production was normal (data not shown).
On the other hand, CD4+ T cells isolated from the pa-
tient’s PBMCs failed to produce detectable amounts of
IFNg when stimulated with IL-12 plus IL-18, a potent
IFNg inducer for T cells (Figure 1A). The failure could
not be attributed to a total defect in the machinery for
IFNg production, because the patient’s T cells produced
considerable amounts of IFNg in response to a combina-
tion of phorbol 12-myristate 13-acetate (PMA) and iono-
mycin, although the amount was a bit lower than normal
(Figure 1A). Furthermore, IL-18 signaling appeared to be
intact in the patient’s T cells, as assessed by IkBa degra-
dation in response to IL-18 stimulation (Figure 1B), im-
plying a defect in the IL-12 signal. Indeed, the patient’s
T cells showed almost no response to IL-12 in contrast
to those from a normal subject, as judged by the tyrosine
phosphorylation of STAT4, a component of the IL-12 sig-
naling pathway (Figure 1C). Interestingly, the patient’s
T cells also failed to respond to IFNa (Figure 1C). This
finding was in sharp contrast to human IL-12Rb1 defi-
ciency, the only known human defect in IL-12 signaling,
in which STAT4 phosphorylation is defective in response
to IL-12, but its phosphorylation is intact in response to
IFNa (Fieschi et al., 2004).
A Homozygous Mutation in the Patient’s Tyk2 Gene
The defect in both IL-12 and IFNa signaling strongly sug-
gested an abnormality in one or more molecules in-
volved in a signaling pathway shared by both cytokines.
STAT4 was a good candidate; however, STAT4 was ex-
pressed at a normal amount in the patient’s T cells (Fig-
ure 1C), and no sequence alteration was found in the
coding region of the STAT4 gene (data not shown).The second candidate we investigated was Tyk2, be-
cause a mutant human cell line unresponsive to IFNa
turned out be deficient in Tyk2 (Velazquez et al., 1992),
even though Tyk2 appeared to be not absolutely essen-
tial for IL-12 and IFNa signals in mice (Karaghiosoff et al.,
2000; Shimoda et al., 2000). Sequencing of the patient’s
cDNA and genomic DNA coding for Tyk2 revealed a ho-
mozygous deletion of four nucleotides, GCTT, at nt 550–
553, that was not found in 50 unrelated healthy individ-
uals (Figures 2A and 2B). This deletion resulted in
a frame-shift mutation from codon 70 to 89 and gener-
ated a premature stop codon at aa 90 in the 1187 amino
acid-long Tyk2 protein (Figure 2B). The predicted trun-
cation of Tyk2 deletes most of the protein, including
Figure 1. Impaired Responses to IL-12 and IFNa in a Patient with
HIES
(A) The patient’s T cells were defective in IFNg production in re-
sponse to IL-12 and IL-18. The concentration of IFNg in culture su-
pernatants was measured after CD4+ T cells from a healthy control
and the patient were cultured for 24 hr with medium alone, a combi-
nation of PMA and ionomycin, or a combination of IL-12 and IL-18.
White bars indicate a control, and black bars indicate the patient.
Error bars are standard deviations.
(B) The patient’s T cells had intact IL-18 signaling. IkBa and a-tubulin
proteins were detected by immunoblotting at the indicated time
points after the T cells from a control subject and the patient were
stimulated with IL-18.
(C) The patient’s T cells had defects in both IL-12 and IFNa signaling.
Tyrosine 694-phosphorylated and total STAT4 proteins were de-
tected by immunoblotting after the T cells from a control subject
and the patient were stimulated with IL-12 or IFNa for 15 min. Results
are representative of at least three independent experiments.
Immunity
748Figure 2. A Homozygous Mutation of the
Tyk2 Gene in the Patient
(A) Electropherograms show the part of the
Tyk2 cDNA sequences from a control subject
and the patient, from which a deletion of four
nucleotides, GCTT, was found in the patient.
(B) The structure of Tyk2 is shown schemati-
cally, and the mutation is indicated: the 4-
nucleotide deletion (above) and the frame-
shift and truncation of the protein (below).
(C) The Tyk2 protein was undetectable in the
patient’s T cells. Tyk2 and a-tubulin proteins
in the T cells from a healthy control subject
and the patient were detected by immuno-
blotting.
(D) The patient was homozygous for the mu-
tation, and both parents were heterozygous
for it. WT, wild-type Tyk2; mt, mutated Tyk2.the FERM domain, the SH2 domain, and the pseudo-
kinase and kinase domains. Indeed, no Tyk2 protein
was detected by immunoblotting with two specific anti-
bodies that recognize different regions of Tyk2 (Fig-
ure 2C). Both parents of the patient were apparently
healthy and showed normal amounts of serum IgE, but
the analysis of genomic DNAs from the parents revealed
that both were heterozygous for the same deletion
(Figure 2D), establishing that the patient had an autoso-
mal recessive Tyk2 deficiency.
Tyk2 Is Indispensable for Type I IFN Signaling
in Humans
Stimulation of the patient’s T cells with various concen-
trations of IFNa or IFNb up to 50 ng/ml (equivalent to
10,000 IU/ml) failed to induce tyrosine phosphorylation
of not only STAT4 (Figure 1C) but also Jak1, STAT1,
STAT2, and STAT3 (Figure 3A and see Figure S1 in the
Supplemental Data available online), in contrast to the
observation in Tyk22/2 mice (Karaghiosoff et al., 2000;
Shimoda et al., 2000). Furthermore, no tyrosine phos-
phorylation of STAT1 and STAT2 was detected at any
time points (5, 15, 30, and 60 min) after the treatment
with IFNs (Figure S2). Interestingly, the amount of
STAT1 protein was reduced in the patient’s T cells in ac-
cord with the observations in Tyk2-deficient mice (Kara-
ghiosoff et al., 2000), whereas those of STAT2, STAT3,
and STAT4 proteins appeared unaffected (Figures 1C
and 3A, and Figure S3). The patient’s T cells displayed
a reduced amount of surface IFNAR1 expression (Fig-
ure S4). This is consistent with previous observations
in a Tyk2-deficient human cell line but in contrast with
that in the Tyk2-deficient mice (Gauzzi et al., 1997; Kara-
ghiosoff et al., 2000; Shimoda et al., 2000). Tyk2 has been
shown to stabilize IFNAR1 at the cell surface in human
cells (Gauzzi et al., 1997; Ragimbeau et al., 2003). Thus,
the defect in the type I IFN signaling in the patient’s cells
could be explained by the absence of Tyk2 accompanied
with reduced amounts of STAT1 and IFNAR1.
Consistent with the signaling defects, the transcrip-
tional upregulation of a panel of IFN-inducible genesincluding NMI and MxA, in response to IFNa or IFNb,
was completely abrogated in PBMCs from the patient
(Figure 3B and Figure S5). We further investigated bio-
logical consequences of the compromised IFN signal-
ing. The upregulation of HLA class I expression in re-
sponse to IFNa was not observed in patient PBMCs
(Figure 3C). Unexpectedly, the patient’s cells displayed
a higher basal amount of HLA class I expression than
the control cells, suggesting a possible compensatory
mechanism to regulate expression in a type I IFN-inde-
pendent manner under conditions of the Tyk2 defi-
ciency. Even at high concentrations, neither IFNa nor
IFNb produced any antiviral protection against herpes
simplex virus (HSV) within the patient B cells (Figures
3D and 3E). Thus, human Tyk2 deficiency showed a
complete defect in type I IFN responses under our ex-
perimental conditions, in contrast to observations in
Tyk22/2 mice (Karaghiosoff et al., 2000; Shimoda et al.,
2000).
We next examined the response to IFNg in the patient
(Figure 3F). Stimulation with IFNg upregulated the tran-
scription of two IFNg-responsive genes, IRF1 and
RING4, in PBMCs from the patient and from a healthy
control. However, the extent of the induction was
much smaller in the patient’s PBMC sample, in accord
with the impairment of IFNg signaling reported in
Tyk22/2 mice (Karaghiosoff et al., 2000).
Tyk2 Is Critical for IL-23, IL-6, and IL-10 Signaling
in Humans
We next examined the response to IL-23 in the patient’s
cells, because IL-23 shares signaling pathways with IL-
12 (Watford et al., 2004). The patient’s T cells showed no
detectable tyrosine phosphorylation of STAT4 in re-
sponse to IL-23 even at high concentrations (500 ng/
ml) in contrast to T cells from a control subject (Fig-
ure 4A). Control T cells secreted IFNg in response to
IL-23 in a dose-dependent manner (Figure 4B) as re-
ported previously (Oppmann et al., 2000). In contrast,
the patient’s T cells showed no response to IL-23 in
IFNg secretion even though the background amount of
Human Tyk2 Deficiency
749Figure 3. Defects in the Type I and II IFN Signals in the Patient’s T Cells
(A) No detectable phosphorylation of the Jak and STAT molecules in the patient’s T cells was seen upon stimulation with type I IFN. The indicated
proteins (p, phosphorylated form) were detected by immunoblotting after the T cells from a control subject and the patient were stimulated with
or without 50 ng/ml (equivalent to 10,000 IU/ml) of IFNa or IFNb for 15 min.
(B) There was no detectable upregulation of the IFN-inducible gene expression in the patient’s cells upon stimulation with type I IFN. The
amounts of NMI, MxA, and cyclophilin B transcripts were evaluated by semiquantitative RT-PCR after PBMCs from a control subject and the
patient were stimulated or not with IFNa or IFNb for 2 hr.
(C) No detectable upregulation of HLA class I in the patient’s cells upon stimulation with type I IFN. The level of HLA class I on PBMCs from a con-
trol subject and the patient was determined with flow cytometry after the cells were cultured with (histograms with thick gray lines) or without
(histograms with thin black lines) IFNa for 48 hr. Histograms with dotted lines show the control staining with an isotype-matched mAb.
(D and E) No antiviral activity was detected in the patient’s B cells upon stimulation with type I IFN. EBV-transformed B cells from a control subject
and the patient were treated for 24 hr with indicated concentrations of IFNa (D) or IFNb (E) prior to the infection with HSV. The viral titers in culture
supernatant of 0 and 48 hr culture were measured by plaque assay with Vero cells. Data are representative of two independent experiments. Error
bars are standard deviations.
(F) Impaired response to IFNg in the patient’s cells. The amounts of IRF1, RING4, and cyclophilin B transcripts were evaluated by semiquanti-
tative RT-PCR, after PBMCs from a control subject and the patient were stimulated with the indicated concentration of IFNg for 2 hr.IFNg was slightly higher in the patient’s T cells than in
the control T cells (Figure 4B). These results indicated
that human Tyk2 played an essential role in IL-23 signal-
ing, in accord with observations in the Tyk2-deficient
mice (Shaw et al., 2003).
It has been demonstrated that Tyk2 is also activated
upon stimulation with IL-6 or IL-10 (Ihle, 1995; Stahl
et al., 1994). PBMCs from the patient failed to upregulate
SOCS3 transcripts in response to IL-6 stimulation
(Figure 4C). They secreted IgM when stimulated by in-
fection with Epstein-Barr Virus (EBV), as did thosefrom a healthy control subject. However, further stimula-
tion with IL-6 induced only a little increase in IgM secre-
tion from the patient’s PBMCs, although IgM secretion
did increase 3 times in the control PBMCs (Figure 4D).
The patient’s PBMCs had a very poor response to
IL-10 stimulation in their induction of SOCS3 (Figure 4E).
Moreover, the inhibition of LPS-induced TNFa produc-
tion by IL-10 was severely impaired in macrophages
from the patient (Figure 4F). These results indicated
that Tyk2 plays an obligatory role in signaling of IL-6
and IL-10 in humans, in contrast to Tyk22/2 mice, which
Immunity
750Figure 4. Defects in IL-23, IL-6, and IL-10
Signals in the Patient’s Cells
(A) The patient’s T cells showed impaired
IL-23 signaling. Tyrosine phosphorylated
and total STAT4 proteins were detected by
immunoblotting after the T cells from a control
subject and the patient were stimulated with
IL-23 (500 ng/ml) for 15 min.
(B) The patient’s T cells showed no substan-
tial response to IL-23 in the IFNg production.
The concentration of IFNg in culture superna-
tants was determined by ELISA after the T
cells from a control subject and the patient
were cultured with the indicated concentra-
tions of IL-23 for 48 hr. White bars indicate
a control, and black bars indicate the patient.
Error bars are standard deviations.
(C) No detectable upregulation of the SOCS3
gene expression in the patient’s cells upon
stimulation with IL-6. The amounts of SOCS3
and cyclophilin B transcripts were evaluated
by semiquantitative RT-PCR after PBMCs
from a control subject and from the patient
were stimulated with or without IL-6 for 4 hr.
(D) Little enhancement of IgM secretion in the
patient’s B cells upon stimulation with IL-6.
The concentration of IgM in the culture super-
natants was determined by ELISA after
PBMCs from a control subject and the patient
were cultured for 10 days with or without
Epstein-Barr virus (EBV), alone or in combina-
tion with IL-6. White bars indicate a control, and black bars indicate the patient. Error bars are standard deviations.
(E) Poor upregulation of the SOCS3 gene expression in the patient’s cells upon stimulation with IL-10. The amounts of SOCS3 and cyclophilin B
transcripts were evaluated by semiquantitative RT-PCR after PBMCs from a control and the patient were cultured with or without IL-10 for 4 hr.
(F) Poor inhibition of LPS-induced TNFaproduction by IL-10 in the patient’s macrophages. The concentration of TNFa in the culture supernatants
was determined by ELISA after macrophages derived from a control subject’s and the patient’s PBMCs were cultured with or without IL-10 for 24
hr, and then stimulated or not with LPS for 48 hr. White bars indicate a control, and black bars indicate the patient. Error bars are standard
deviations. Results are representative of at least three independent experiments.respond normally to IL-6 (Karaghiosoff et al., 2000;
Shimoda et al., 2000). Tyk22/2 mice were originally re-
ported to respond normally to IL-10 (Karaghiosoff
et al., 2000; Shimoda et al., 2000), while a recent study
demonstrates partial impairment in IL-10 signaling
(Shaw et al., 2006).
Imbalance in Th1 and Th2 Differentiation
in the Patient
We next examined in vitro the Th1 and Th2 differentia-
tion of T cells from the patient (Figure 5), because the pa-
tient displayed Th2-dominant phenotypes such as
atopic dermatitis and highly elevated serum IgE. Even
under Th1-biased culture conditions, the frequency of
IFNg-producing Th1 cells remained low in the patient’s
T cells (Figure 5A, middle). On the other hand, their dif-
ferentiation into IL-4-producing Th2 cells under Th2-
biased culture conditions appeared to be accelerated
(Figure 5A, right). When cultured for 14 days in the pres-
ence of anti-CD3 and IL-2, the patient’s T cells showed
helper T cell differentiation that was extremely skewed
toward Th2, compared with the control T cells
(Figure 5B). Naive CD4+ T cells isolated from the pa-
tient’s PBMCs showed reduced secretion of IFNg and
enhanced secretion of IL-5 and IL-13 as compared to
the control T cells when stimulated with anti-CD3 and
anti-CD28 (Figure 5C). These results clearly indicated
that Tyk2 is critical for the IL-12-induced Th1 differenti-
ation and represses the development of Th2 cells, inaccord with the observations in mice (Seto et al., 2003;
Shaw et al., 2003).
Expression of the Intact Tyk2 Gene Rescues
the Patient’s T Cells from Defects in IL-12 and
Type I IFN Signaling
The wild-type Tyk2 gene in a retroviral vector was intro-
duced into activated primary T cells from the patient.
The infected T cells acquired the expression of Tyk2
proteins at approximately 70% of the normal amount
(Figure 6A). Upon combined stimulation with the IL-12
and IL-18, the infected Tyk-2-expressing cells produced
IFNg, as did T cells from a normal control subject (Fig-
ure 6B). In contrast, the patient’s T cells infected with vi-
rus carrying the empty vector did not produce IFNg in re-
sponse to this stimulation, nor did uninfected cells.
Furthermore, Tyk2-infected T cells from the patient ac-
quired the ability to upregulate the transcription of
MxA in response to IFNa (Figure 6C). A complementary
experiment was performed in which human Hela cells
were subjected to the knockdown of Tyk2 gene expres-
sion with siRNAs. In cells treated with Tyk2-specific
siRNAs, the tyrosine phosphorylation of STAT1 and
STAT2 in response to IFNawas almost completely abro-
gated, concomitantly with the suppression of Tyk2 ex-
pression, as observed in the patient’s cells (Figure S6).
These results indicated that the defects in the IL-12
and type I IFN signaling observed in the patient’s T cells
were caused primarily by the absence of functional Tyk2.
Human Tyk2 Deficiency
751Figure 5. Impaired Th1 and Accelerated Th2
Differentiation in the Patient’s T Cells
(A) Intracellular staining with anti-IFNg and
anti-IL-4 was performed after PBMCs from
a control subject and the patient were stimu-
lated with immobilized anti-CD3 alone, in
combination with IL-12 and anti-IL-4 (Th1-
promoting condition) or in combination with
IL-4 (Th2-promoting condition) for 5 days.
The percentage of IFNg- or IL-4-producing
cells is shown in each panel.
(B) PBMCs from a control subject and the pa-
tient were stimulated with immobilized anti-
CD3 and IL-2 for 14 days, and intracellular
staining was performed as in (A).
(C) Naive CD4+ T cells from a control subject
and the patient were stimulated with anti-
CD3 and anti-CD28 for 3 days, and the con-
centration of IFNg, IL-5, and IL-13 in culture
supernatants was measured by ELISA. White
bars indicate a control, and black bars indi-
cate the patient. Error bars are standard devi-
ations. Results are representative of at least
three independent experiments.Discussion
We have identified a human deficiency in Tyk2. Among
the four members of the Jak family, Jak3 deficiency
was previously reported in human, demonstrating the
crucial role of Jak3 in lymphocyte development, in ac-
cord with findings in Jak3-deficient mice (Macchi et al.,
1995; Nosaka et al., 1995; Park et al., 1995; Russell
et al., 1995). The identification of a human Tyk2 defi-
ciency highlighted the obligatory roles of human Tyk2
in multiple cytokine signals involved in innate and ac-
quired immune responses, including type I IFN, IL-6,
IL-10, IL-12, and IL-23 signals. Although Tyk2 is ubiqui-
tously expressed (unlike Jak3), the Tyk2 deficiency dis-
played apparently normal embryogenesis, postnatal
growth, and hematopoiesis ,while it resulted in a primary
immunodeficiency with clinical manifestations charac-
teristic to HIES, indicating a unique and indispensable
role played by Tyk2 in the immune system.
The present study contrasted differences in the strin-
gency of Tyk2 requirement between human and mice.
The nonredundant roles of human Tyk2 in multiple cyto-
kine signals in vivo could not be assumed from the stud-
ies on mouse Tyk2. The Tyk22/2 mice responded nor-
mally to IL-6, even though IL-6 activated Tyk2 in vitro.
The mice also showed a leaky phenotype in type I IFN re-
sponses: a high concentration of IFNa showed antiviral
effects and upregulated MHC class I expression in cells
from the Tyk22/2 mice to an extent comparable to that
observed in wild-type mice (Karaghiosoff et al., 2000;
Shimoda et al., 2000). This was a sharp contrast to the
observation in human Tyk2-deficient fibroblast cell
lines. Our results indicated that the discrepancy be-
tween these two observations was due to a species dif-
ference rather than the difference between primary cells
and particular cultured cell lines. We observed no de-
tectable tyrosine phosphorylation of Jak1 in response
to type I IFN in the human Tyk2 deficiency, supporting
the idea that Tyk2 and Jak1 transphosphorylate eachother, and hence both are independently required for
the initial activation of IFN signaling. In contrast, in the
mouse Tyk2 deficiency, the Jak1 phosphorylation was
observed when stimulated with type I IFN, albeit to
a lesser extent than in wild-type mice. Thus, Tyk2 is
the obligatory requirement for the initiation of type I
IFN signaling in human whereas it is redundant in the ini-
tiation and might function as an amplifier of signaling in
mice. This also appears to be the case in the IL-12 sig-
naling. Tyk22/2 mice showed compromised signaling
and biological effects in response to IL-12 (Karaghiosoff
et al., 2000; Seto et al., 2003; Shaw et al., 2003; Shimoda
et al., 2000), but the impairment was less drastic than
that observed in IL-12 receptor-deficient mice (Wu
et al., 1997).
The in vitro findings of defects in multiple cytokine sig-
nals due to the Tyk2 deficiency appeared to account for
the complex clinical manifestations of the patient inves-
tigated in the present study. First, the susceptibility to vi-
ral infection could be attributed to the defect in IFN sig-
naling. Indeed, even a high titer of type I IFNs did not
show any protective effect against herpes simplex virus
in the patient’s cells, unlike in Tyk22/2 mice (Karaghios-
off et al., 2000; Shimoda et al., 2000). Interestingly, the
response to type II IFN (IFNg) stimulation was also im-
paired in the patient’s T cells, albeit to a lesser extent,
even though Tyk2 has not been assigned to the type II
IFN signaling pathway. The partial impairment of IFNg
signaling could be explained, at least in part, by the re-
duced amounts of STAT1 protein or by the observation
that IFNg signaling depends on constitutive subthresh-
old type I IFN signaling (Takaoka et al., 2000). Thus,
the type II IFN response is reduced but not absent in
the Tyk2 deficiency in contrast to its complete lack in
the STAT1 deficiency (Dupuis et al., 2003), even though
the type I IFN response is absent in both deficiencies.
This could account for the apparently milder phenotype
of the Tyk2 deficiency in viral infections, compared to
the lethal phenotype of the STAT1 deficiency. It remains
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IL-29) signaling is defective in the Tyk2 deficiency.
Second, the susceptibility of the patient to infection
with intracellular bacteria, such as mycobacteria and
salmonella, could be explained by the defect in IL-12
signaling, as seen in IL-12Rb1 deficiency (Altare et al.,
1998; de Jong et al., 1998). The differentiation into Th1
cells, which are important for the elimination of these
bacteria, was severely impaired in the patient’s T cells,
even under culture conditions that strongly promote
the differentiation of Th1 cells. Given that type I IFNs
promote Th1 differentiation in humans and not in mice,
the defect in the IFN signal might also account in part
for the failure of Th1 differentiation in this patient. The
susceptibility of Tyk2 knockout mice to infection of in-
tracellular bacterial has not been reported, but a natural
mutant strain B10.Q/J, which is susceptible to toxo-
plasma infection and resistant to induction of autoim-
mune arthritis, was reported to carry Tyk2 mutation
Figure 6. Transduction of the Intact Tyk2 Gene Rescued the
Patient’s T Cells from Defects in the IL-12 and Type I IFN Signals
(A) Reconstitution of Tyk2 in the patient’s T cells. T cells from the pa-
tient and a control subject were infected with either the empty retro-
viral vector (pMX-IG) or the Tyk2 cDNA-containing vector (pMX-IG-
Tyk2). The protein expression of Tyk2 and tubulin in GFP+-infected
cells were detected by immunoblotting.
(B) Retrovirus-mediated Tyk2 transfer restored the IFNg production
in response to IL-12 and IL-18 in the patient’s T cells. The production
of IFNg was detected by intracellular staining with an IFNg mAb in
uninfected and infected T cells after stimulation with IL-12 and IL-
18 for 48 hr. Histograms with thick gray lines show the staining pro-
file of GFP+-infected cells, and those with thin black lines show the
staining profile of GFP2 uninfected cells. Histograms with dotted
lines show the control staining with an isotype-matched mAb.
(C) Retrovirus-mediated Tyk2 transfer restored the upregulation of
IFN-inducible gene expression in response to IFNa in the patient’s
T cells. The amounts of MxA and cyclophilin B transcripts were eval-
uated by semiquantitative RT-PCR after stimulation of the indicated
T cells with IFNa for 2 hr. Results are representative of at least three
independent experiments.(Shaw et al., 2003). Mice deficient for IL-23 showed the
susceptibility to Klebsiella pneumonia owing to their im-
pairment in IL-17 production by T cells (Happel et al.,
2005). Therefore, the patient’s susceptibility to extracel-
lular bacteria might be explained at least in part by the
defect in IL-23 signaling.
Third, the high amount of serum IgE and the atopic der-
matitis-like skin inflammation in the patient could be due
to the accelerated Th2 differentiation. Indeed, the Tyk2
deficiency was shown to accelerate Th2-mediated aller-
gic airway inflammation in mice (Seto et al., 2003). In
a previous report, enhanced Th2 differentiation was not
observed in an IL-12Rb1 deficiency, although the Th1 dif-
ferentiation was severely impaired (Wood et al., 2005).
Thus, the defect in IL-12 signaling does not account for
the abnormally accelerated Th2 differentiation in the
Tyk2-deficient patient. PBMCs and macrophages from
the patient showed a severe signaling defect in the IL-
10 pathway. IL-10 has been reported to suppress the dif-
ferentiation of both Th1 and Th2 cells, so the defect in the
IL-10 pathway might explain, at least in part, the acceler-
ated Th2 differentiation under conditions in which Th1
differentiation was defective as observed in mice defi-
cient for both IL-10 and IL-12 (Hoffmann et al., 2000).
The patient investigated in the present study had been
clinically diagnosed as HIES, fulfilling the criteria for the
diagnosis according to the NIH scoring system (Grim-
bacher et al., 1999b). HIES is a primary immunodefi-
ciency with unknown etiology, characterized typically
by high serum IgE amounts, recurrent staphylococcal
skin abscesses, and pneumonia with pneumatocele for-
mation (Grimbacher et al., 2005). While most cases of
HIES are sporadic, families displaying autosomal domi-
nant (AD) or autosomal recessive (AR) inheritance have
been reported (Grimbacher et al., 1999a; Renner et al.,
2004). In most sporadic and AD cases, these clinical
manifestations are part of a multisystem disorder includ-
ing abnormalities of the soft tissue, skeletal, and dental
systems (Grimbacher et al., 1999a). In contrast, patients
with AR-HIES lack skeletal and dental involvement and
lung cyst formation and suffer from fungal and viral infec-
tions such as herpes simplex and molluscum contagio-
sum (Renner et al., 2004). According to this classification,
the present case could be categorized into the AR-HIES.
It is notable that the infection with intracellular bacteria
experienced by the present case has not been frequently
observed in HIES patients, even though three cases with
mycobacterial infection were reported in the literatures
(Grimbacher et al., 1999a; Metin et al., 2004; Pasic
et al., 1998). Therefore, we would like to propose that
the present case represents a subset of the AR-HIES.
The whole picture of HIES including its etiology has not
yet drawn clearly, so further genetic analyses of HIES is
needed to evaluate this proposal and define the Tyk2 de-
ficiency as either a variant of HIES or a distinct disease
entity. In either case, the present study highlighted a req-
uisite and nonredundant role played by Tyk2 in the innate
and acquired immune responses in human.
Experimental Procedures
Patient
This study was approved by the institutional review board at the
Tokyo Medical and Dental University. Written informed consent
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753was obtained from all the subjects studied. The patient investigated
in this study is a 22-year-old Japanese male with a history of infantile
atopic dermatitis starting from 1 month of age and recurrent infec-
tions, such as otitis media, sinusitis, pneumonias, and skin ab-
scesses, starting from 12 months of age. At 22 months, he devel-
oped BCG lymphadenitis. Histological examination revealed
paucibacillary, well-circumscribed granulomas with epithelioid and
giant multinucleated cells, as observed in the human IL-12Rb1 defi-
ciency (Altare et al., 1998; de Jong et al., 1998). The immunological
work-up performed at this occasion revealed mild eosinophilia
(700–800/mm3) and high serum IgE (2100 IU/ml) with normal
amounts of other Ig classes and subclasses. All other laboratory
data examined were within the normal range, including complement
components, the oxidative burst of granulocytes, the number and
the size of platelets, lymphocyte subpopulations, and their prolifer-
ative responses to mitogens. The patient’s illness was tentatively di-
agnosed as HIES though he did not show any apparent skeletal
abnormality. Thereafter, in addition to infections with bacteria in-
cluding Staphylococcus aureus, he recurrently suffered from viral
and fungal infections, such as molluscum contagiosum, herpes sim-
plex infection of skin and mucosa, and oral candidiasis. At 15 years
of age, the patient developed severe non-typhi salmonella gastroen-
teritis leading to sepsis. According to the HIES scoring system
(Grimbacher et al., 1999b), the patient gained 48 points; 10 in IgE
titers, 8 in skin abscess, 8 in pneumonia, 3 in eosinophil count, 4 in
newborn rash, 4 in eczema, 2 in upper respiratory infection, 1 in
oral candidiasis, 4 in other serious infections, and 4 in fatal infection.
Antibodies and Cytokines
The mAbs for the N-terminal region (aa 46–258) of human Tyk2, IL-
12Rb1, IL-12Rb2, IkBa, IL-4, and IFNg were purchased from BD
Pharmingen, and the CD3 mAb (OKT3) was from Janssen Pharma-
ceutical. The Ab for the C-terminal region of Tyk2 (C-8) was from
Santa Cruz. Rabbit antibodies for Jak1, STAT1, STAT2, STAT3,
and STAT4 and their phosphorylated forms were purchased from
Cell Signaling. Anti-IFNAR1 was from R&D Systems. HRP-conju-
gated rabbit anti-mouse and goat anti-rabbit antibodies were from
Calbiochem, and mouse anti-a-tubulin was from Sigma-Aldrich.
Recombinant human IL-4, IL-12, IFNa, IFNb, IFNg, and GM-CSF
were purchased from Peprotech, recombinant human IL-2 was from
Shionogi, and IL-18 was from MBL.
Isolation and Culture of T Cells and Macrophages from PBMCs
Heparinized blood samples were obtained from the patient and from
healthy age-matched control subjects. PBMCs were isolated from
blood samples through density gradient centrifugation via Histopa-
que-1077 (Sigma-Aldrich). For T cell activation, PBMCs were cul-
tured with 5 mg/ml plate-bound CD3 mAb and 300 U/ml IL-2 in
RPMI 1640 (Sigma-Aldrich) containing 10% fetal bovine serum
(FBS), 50 mM 2-mercaptoethanol (Life Technologies), 2% L-gluta-
mine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids,
and 1% penicillin-streptomycin. CD4+ T cells were enriched with im-
munomagnetic beads (BD Pharmingen) with more than 98% purity.
After 14 days of culture, more than 98% of the cells from both
the patient and control subjects were effector memory T cells
(CD45RO+CCR72). Naive CD4+ T cells were purified by removing
CD45RO+ cells from CD4+ T cells by immunomagnetic beads (BD
Pharmingen) with more than 90% purity. To obtain macrophages,
PBMCs were cultured for 2 hr, and the adherent cells were further
cultured with 10 ng/ml GM-CSF for 7 days as described (Hart
et al., 1995). All the experiments were performed at least three times
with three different controls.
Construction of Retroviral Vectors and Infection of Cells
The retroviral vector pMX-IRES-GFP-Tyk2 was constructed by in-
serting the Tyk2 cDNA into the BamHI and NotI sites of the pMX-
IRES-GFP vector (a gift from T. Kitamura) (Nosaka et al., 1999). Infec-
tious retroviral particles were generated with the Plat-GP cell line (a
gift from T. Kitamura and H. Miyoshi). Retroviral supernatant stocks
were produced by culturing the producer cells at 37C for 72 hr. For
the infection, PBMCs were stimulated in culture with 5 mg/ml plate-
bound CD3 mAb and 300 IU/ml IL-2. Cells (1 3 106/ml) were then
spin-infected with the retroviral supernatant at 32C for 30 min.
The transduction procedure was repeated on days 2 and 3. Theefficiency of infection was approximately 3% as judged by the
frequency of GFP+ cells.
Tyk2 Knockdown
RNA interference for Tyk2 was designed with the aid of the online
software from Invitrogen. The sequences of siRNA sense strands
(50 / 30) were as follows: Tyk2 siRNA1, CCCAGAGAUGCAAGCCU
GAUGCUAU, and Tyk2 siRNA2, CCAUUCUGAAGACAGUCCAUGA
GAA. Hela cells were grown in DMEM supplemented with 10%
FBS. Transfection of the cells with siRNAs was performed with
Lipofectamine-RNAiMAX reagent (Invitrogen). 48 hr after transfec-
tion, the cells were treated with IFNa (50 ng/ml) for 15 min before
lysis. Lysates were analyzed by immunoblotting with the antibodies
indicated.
RT-PCR and Direct Sequence Analysis
Extraction of total RNA, cDNA synthesis, PCR, and semiquantitative
RT-PCR were performed as previously described (Minegishi et al.,
1999a). PCR primers were designed as follows: Tyk2, sense, 50-
TTGCTTGAGTTGACACAGGGAGCT-30, antisense, 50-TCTCTAGAC
AGGAGTAAGGCACAC-30; STAT4, sense, 50-CTGGGACCTGTGCTG
AGAGAGC-30, antisense, 50-ACTTTTTCATTTGCTTCCTT-30; NMI,
sense, 50-TTAAGGAGCATTCGCCAGAT-30, antisense, 50-TTCGAGC
TCACTTGAAACGA-30, MxA, sense, 50-GAGGTGCAGGAGAACAG
CTC-30, antisense 50-CTCCTCATACTGGCTGCACA-30; cyclophilin
B, sense, 50-GCCCAAAGTCACCGTCAAGG-30, antisense, 50-GGAA
GCGCTCACCGTAGATG-30; IRF1, sense, 50-GCTGGGACATCAACA
AGGAT-30, antisense, 50-GTGGAAGCATCCGGTACACT-30; RING4,
sense, 50-AGGGCTGGCTGGCTGCTTTGA-30, antisense, 50-ACGTG
GCCCATGGTGTTGTTAT-30; and SOCS3, sense, 50-TTCAGCTCCA
AGAGCGAGTA-30, antisense, 50-CGGAGTAGATGTAATATGGCTC-
30. Sequencing was performed with an ABI Prism dRhodamine
Terminator kit and analyzed with an ABI Prism 310 DNA Sequencer
(Perkin-Elmer Applied Biosystems).
Stimulation of Cells with Cytokines and the Measurement
of Cytokine and Ig Production
Cells were stimulated for the indicated time in culture with PMA
(40 nM), ionomycin (0.5 mg/ml), IL-12 (10 ng/ml), IL-18 (50 ng/ml),
IFNa (50 ng/ml), IFNb (50 ng/ml), IL-6 (10 ng/ml), or IL-10 (100 ng/
ml). The concentration of IFNg in the culture supernatants was deter-
mined by ELISA (BD-PharMingen) according to the manufacturer’s
instructions, after the cells (1 3 106/ml) were cultured in 96-well
plates at 37C for 24 hr with or without stimulation. The concentra-
tion of TNFa in the culture supernatants was determined by ELISA
(BD-PharMingen), after the cells (1 3 105/well) were cultured in 96-
well plates at 37C for 48 hr with or without stimulation. The mea-
surement of IgM secretion from Epstein-Barr virus-infected B cells
was determined by ELISA as previously described (Minegishi and
Conley, 2001). To evaluate helper T cell differentiation in vitro,
PBMCs were cultured for 5 days with immobilized anti-CD3 alone
or in combination with IL-12 (10 ng/ml) and anti-IL-4 (10 mg/ml) to
promote Th1 differentiation, or in combination with IL-4 (20 ng/ml)
to promote Th2 differentiation, or the PBMCs were cultured for 14
days with immobilized anti-CD3 and IL-2 (300 IU/ml). Alternatively,
naive CD4+ T cells were cultured with immobilized anti-CD3 and
soluble anti-CD28 for 3 days. The concentration of IFNg, IL-5, and
IL-13 in the culture supernatants was determined by ELISA (BD
Pharmingen).
Flow Cytometric Analysis
The surface immunophenotype was analyzed as described (Mine-
gishi et al., 1999a). For cytokine intracellular staining, cells were re-
stimulated with PMA and ionomycin in the presence of 2 mM of mon-
ensin for 5 hr, followed by fixation and cytoplasmic staining with
FITC- or PE-conjugated mAbs specific for the indicated cytokines.
An irrelevant FITC- or PE-conjugated IgG1 mAb was used as the
negative control.
Immunoblotting and Immunoprecipitation
Cells were washed and cultured for 18 hr in starvation medium con-
sisting of RPMI 1640 and 1% FBS. Cells were then stimulated at
37C for 15 min with medium alone, 10 ng/ml IL-12, 50 ng/ml IL-
18, 50 ng/ml IFNa, or 50 ng/ml IFNb. After the stimulation, the cells
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754were lysed on ice for 30 min in lysis buffer containing 1% Triton
X-100, 50 mM Tris (pH 8.0), 150 mM NaCl, 2 mM EDTA, 2 mg/ml apro-
tinin, 100 mg/ml PMSF, 1 mM sodium orthovanadate, and 1 mM NaF.
The cell lysates were subjected to SDS-PAGE, followed by electro-
transfer to PVDF membranes and immunoblotting with the indicated
antibodies.
Antiviral Activity Assay
EBV-transformed B cells were pretreated with or without 0.005, 0.5,
50 ng/ml IFNa or IFNb for 24 hr, and then infected with HSV (103
plaque-forming units/ml). The viral titers in culture supernatants
were determined at the indicated time points by plaque assay with
Vero cells.
Supplemental Data
Six Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/5/745/DC1/.
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